{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:35:22Z","timestamp":1788543322216,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.tcm.2023.02.004","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T01:41:50Z","timestamp":1676598110000},"page":"250-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Conduction system disease in cardiac amyloidosis"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-798X","authenticated-orcid":false,"given":"Ala\u2019","family":"Assaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-5419","authenticated-orcid":false,"given":"Mario","family":"Mekhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Noujaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Chouman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Kreidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassir","family":"Marrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Donnellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2023.02.004_bib0001","article-title":"Epidemiology and clinical manifestations of cardiac amyloidosis","author":"Bajwa","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"11","key":"10.1016\/j.tcm.2023.02.004_bib0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tcm.2023.02.004_bib0003","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2023.02.004_bib0004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amjcard.2020.12.024","article-title":"Impact of arrhythmias on hospitalizations in patients with cardiac amyloidosis","volume":"143","author":"Thakkar","year":"2021","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.tcm.2023.02.004_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000508287","article-title":"Prognosis and staging of AL amyloidosis","volume":"143","author":"Dittrich","year":"2020","journal-title":"Acta Haematol"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2023.02.004_bib0006","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"10.1016\/j.tcm.2023.02.004_bib0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.medcle.2022.08.001","article-title":"Cardiac amyloidosis: description of a series of 143 cases","volume":"159","author":"Barge-Caballero","year":"2022","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"issue":"9","key":"10.1016\/j.tcm.2023.02.004_bib0008","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circulation: Heart Failure"},{"issue":"5","key":"10.1016\/j.tcm.2023.02.004_bib0009","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jmb.2006.10.101","article-title":"Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic\/necrotic pathways","volume":"365","author":"Gharibyan","year":"2007","journal-title":"J Mol Biol"},{"issue":"8","key":"10.1016\/j.tcm.2023.02.004_bib0010","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.tcm.2023.02.004_bib0011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCIMAGING.112.000367","article-title":"Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy","volume":"6","author":"Coutinho","year":"2013","journal-title":"Circ Cardiovasc Imag"},{"issue":"4","key":"10.1016\/j.tcm.2023.02.004_bib0012","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/joa3.12376","article-title":"Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014","volume":"36","author":"Isath","year":"2020","journal-title":"J Arrhythm"},{"issue":"10","key":"10.1016\/j.tcm.2023.02.004_bib0013","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.tcm.2023.02.004_bib0014","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.tcm.2023.02.004_bib0015","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.tcm.2023.02.004_bib0016","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"Jacc-Clin Electrophy"},{"issue":"2","key":"10.1016\/j.tcm.2023.02.004_bib0017","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.tcm.2023.02.004_bib0018","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.tcm.2023.02.004_bib0019","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/pace.13992","article-title":"Catheter ablation of atrial fibrillation in cardiac amyloidosis","volume":"43","author":"Black-Maier","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.tcm.2023.02.004_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.tcm.2023.02.004_bib0021","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.tcm.2023.02.004_bib0022","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2023.02.004_bib0023","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.tcm.2023.02.004_bib0024","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.tcm.2023.02.004_bib0025","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jacep.2020.04.020","article-title":"Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"10.1016\/j.tcm.2023.02.004_bib0026","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"12","key":"10.1016\/j.tcm.2023.02.004_bib0027","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.hrthm.2016.09.027","article-title":"Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function","volume":"13","author":"Kiehl","year":"2016","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.tcm.2023.02.004_bib0028","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/heart.88.6.615","article-title":"Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?","volume":"88","author":"Bernardi","year":"2002","journal-title":"Heart"},{"issue":"18","key":"10.1016\/j.tcm.2023.02.004_bib0029","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.tcm.2023.02.004_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.tcm.2023.02.004_bib0031","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0735-1097(84)80436-2","article-title":"Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities","volume":"3","author":"Falk","year":"1984","journal-title":"J Am Coll Cardiol"},{"issue":"8 Pt 1","key":"10.1016\/j.tcm.2023.02.004_bib0032","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter monitoring in AL amyloidosis: prognostic implications","volume":"24","author":"Palladini","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"issue":"7","key":"10.1016\/j.tcm.2023.02.004_bib0033","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"4","key":"10.1016\/j.tcm.2023.02.004_bib0034","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/pace.14458","article-title":"Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis","volume":"45","author":"Brown","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"issue":"11","key":"10.1016\/j.tcm.2023.02.004_bib0035","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/pace.14023","article-title":"Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis","volume":"43","author":"Donnellan","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"issue":"4","key":"10.1016\/j.tcm.2023.02.004_bib0036","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: CardioOncology State-of-the-Art review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"14","key":"10.1016\/j.tcm.2023.02.004_bib0037","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.tcm.2023.02.004_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"Ne Engl J Med"},{"issue":"4","key":"10.1016\/j.tcm.2023.02.004_bib0039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2017.1374946","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.tcm.2023.02.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017382300021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017382300021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T01:14:41Z","timestamp":1715044481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105017382300021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S105017382300021X"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2023.02.004","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conduction system disease in cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2023.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}